Suppr超能文献

基于外泌体的纳米平台:乳腺癌治疗的新兴工具

Exosome-Based Nanoplatforms: The Emerging Tools for Breast Cancer Therapy.

作者信息

Liu Quan, Zhang Xian, Zhang Jun

机构信息

Department of Thyroid and Breast Surgery, Xiantao First People's Hospital Affiliated to Yangtze University, Xiantao, China.

Ningxia Key Laboratory of Cerebrocranial Diseases, Incubation Base of the National Key Laboratory, Ningxia Medical University, Yinchuan, China.

出版信息

Front Oncol. 2022 Apr 28;12:898605. doi: 10.3389/fonc.2022.898605. eCollection 2022.

Abstract

Breast cancer (BC) remains the leading malignant tumor type among females worldwide. The patients with BC are still faced with undesirable metastasis, relapse rate, and drug resistance. Exosomes are defined as naturally occurring extracellular vesicles (EVs) with typical biomarkers that reflect the characteristics of the parent cells. Exosomes are crucial mediators involved in intercellular communication. By transferring multiple cargoes, represented by proteins, nucleic acids, lipids, metabolites, exosomes contribute to reshaping the recipient cell function and fate. Growing evidence has documented that exosomes originating from BC cells are important participants involved in BC progression and treatments. Nanoparticle-based technology is the cutting-edge field for renewing pharmaceuticals and has endowed deep improvements in precise BC treatment. Additionally, due to their perfect features of the low immune prototype, limited adverse effects, prolongated circulation, and easy modification, exosomes have received much attention as candidates in nano-medicine of BC. The nanoplatforms constructed by exosomes have safety, intelligence, biomimetic, and controlled released advantages for combating BC. Here, we emphasize the multiple exosomes from a variety of cell sources in constructing nanoplatforms for BC therapy, mainly including exosomes and their cargoes, genetically engineered exosomes, and exosome-based carriers. This field would shed light on the promising exosome-based delivery system in BC therapy.

摘要

乳腺癌(BC)仍然是全球女性中最主要的恶性肿瘤类型。BC患者仍面临着不良的转移、复发率和耐药性问题。外泌体被定义为天然存在的细胞外囊泡(EVs),具有反映母细胞特征的典型生物标志物。外泌体是参与细胞间通讯的关键介质。通过转运以蛋白质、核酸、脂质、代谢物为代表的多种货物,外泌体有助于重塑受体细胞的功能和命运。越来越多的证据表明,源自BC细胞的外泌体是参与BC进展和治疗的重要参与者。基于纳米颗粒的技术是药物更新的前沿领域,并在精准BC治疗方面有了深入改进。此外,由于外泌体具有低免疫原性、不良反应有限、循环时间延长和易于修饰等完美特性,其作为BC纳米医学的候选者受到了广泛关注。由外泌体构建的纳米平台在对抗BC方面具有安全性、智能性、仿生和控释优势。在此,我们强调了多种细胞来源的外泌体在构建用于BC治疗的纳米平台中的作用,主要包括外泌体及其货物、基因工程外泌体和基于外泌体的载体。该领域将为BC治疗中基于外泌体的有前景的递送系统提供启示。

相似文献

2
Exosome vesicle as a nano-therapeutic carrier for breast cancer.外泌体囊泡作为一种用于乳腺癌治疗的纳米载体。
J Drug Target. 2021 Feb;29(2):121-130. doi: 10.1080/1061186X.2020.1808001. Epub 2020 Aug 26.

引用本文的文献

本文引用的文献

6
Artificial exosomes for translational nanomedicine.人工外泌体用于转化纳米医学。
J Nanobiotechnology. 2021 Aug 12;19(1):242. doi: 10.1186/s12951-021-00986-2.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验